Central Pharma Biotechnica Limited
Registered name: CENTRAL PHARMA BIOTECHNICA LIMITED
Part of Central Pharma Contract Holdings Limited groupCentral Pharma Biotechnica Limited made £563k revenue and a £307k loss in the year to 31 Dec 2024.
Central Pharma Biotechnica Limited’s revenue grew 5% to £563k in the year to 31 Dec 2024, with a loss of £307k and 3 employees. The company is classified under “manufacture of fertilizers and nitrogen compounds” and is based in Bedford; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- Bedford, South East
- Age
- 5 yrs · since 2021
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 |
|---|---|---|---|
| Disclosure | No P&L | Full P&L | Full P&L |
| Profit & loss | |||
| Revenue (turnover) | — | £539k | £563k |
| Cost of sales | — | £327k | £454k |
| Gross profit | — | £212k | £109k |
| Profit before tax | — | −£271k | −£307k |
| Profit after tax | — | −£262k | −£307k |
| Profit (best available) | — | −£262k | −£307k |
| Employees (average) | 8 | 7 | 3 |
| Ratios | |||
| Profit margin | — | −48.6% | −54.6% |
| Gross margin | — | 39.3% | 19.4% |
| Revenue per employee | — | £76.9k | £188k |
| Profit per employee | — | −£37.4k | −£102k |
| Growth (year on year) | |||
| Revenue growth | — | — | ▲4.5% |
| Headcount growth | — | ▼12.5% | ▼57.1% |
| Balance sheet — indirect signals, not revenue | |||
| Cash at bank | £9.8k | £105k | £48.8k |
| Net assets | −£741k | −£1m | −£1.3m |
| Fixed assets | £35.5k | £23.3k | £18.6k |
| Current assets | £312k | £472k | £260k |
| Debtors | £52.1k | £79.9k | £18.5k |
| Source | FullAccounts · bulk data Nov 2024 | FullAccounts · bulk data Nov 2024 | FullAccounts · bulk data Sep 2025 |
How the business works
- Profit margin
- −54.6%
- Profit ÷ revenue.
- Gross margin
- 19.4%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £188k
- Revenue ÷ average employees.
- Profit per employee
- −£102k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 3.3%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 3.3%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£1.3m
- Cash at bank
- ▼53%
- Now £48.8k
- Headcount
- ▼57%
- Now 3
- Deferred income
- —
- Now —
- Fixed assets
- ▼20%
- Now £18.6k
Group structure
Ownership chain
- Central Pharma Contract Holdings Limitedultimate parent75–100%
- Central Pharma Biotechnica Limitedthis company
Bands show the share of ownership each company holds in the one below it.
Sister companies (3)
- Central Pharma Contract Packing LimitedRev. £17.9m · Profit £237k
- Central Pharma Cell and Gene Therapy LtdRev. £513k · Profit −£292k
- Central Pharma Manufacturing LtdFigures not disclosed
From the Persons with Significant Control register (corporate controllers only).
Sources
Latest figures from FullAccounts for the year to 31 Dec 2024 (profit −£307k), from the Companies House accounts bulk data published Sep 2025. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.